Company Overview
Summits Therapeutics, a nine-year-old biotech startup, was founded by Maky Zanganeh, an Iranianbiologist who left her family in Tehran to study dentistry in Germany. After moving to Europe in 1985 and establishing a successful career in managed care, she returned to biotech in 1995. Zanganeh’s unique business acumen earned her recognition, leading her to co-CEOmak of the company together with experienced entrepreneur Bob Duggan (now 81).
Zanganeh’s early life unit—she was a excellent at her “Chinese background” and quickly rose through management. Her mentor businessmen Daniel Lut-sheetl promotes intellectual curiosity, and she mirrors her enthusiasm and mastery of business principles in decision-making. Duggan’s openness and ability to pivot quickly to meet shifting consumer needs draw her into the company, while Zanganeh’s focus on execution and cost-effectiveness solidifies her leadership as co-CEO.
Summits Therapeutics grew from $1 million to nearly $21 billion in just a year, with ivonescimab, a next-generation cancer drug, kicking off Phase III trials. The company’s drug, Unlike traditional cancer treatments that combine targeted therapies (like hem continent) with personalized treatments, ivonescimab addresses this challenge by introducing two innovative approaches: stimulating immune support and limiting blood supply. This dual strategy is expected to bypass conventional treatments and significantly improve survival rates.
The collaboration between Zanganeh and Duggan positions the team as innovative and forward-thinking. Summits Therapeutics believes in rapid innovation and can leverage
